Table 1.
Patient characteristics and preoperative data
| n = 42 | |
|---|---|
| Gender, m/f (ratio) | 23/19 (1.21) |
| Age (average ± SD) | 70.5 ± 11.44 |
| BMI (average ± SD) | 23.97 ± 5.23 |
| Metastatic disease, n (%) | 21 (50) |
| Intra-abdominal metastasis | 14 (33.3) |
| Liver metastasis | 10 (23.8) |
| Extra-abdominal metastasis | 2 (4.7) |
| Locally advanced disease only, n (%) | 21 (50) |
| Comorbidities, n (%) | |
| HTN | 24 (57.14) |
| DM | 17 (40.4) |
| HPL | 17 (40.4) |
| IHD | 9 (21.4) |
| CHF | 2 (4.7) |
| CKD | 3 (7.14) |
| CVA | 4 (9.4) |
| BPH | 3 (7.14) |
| COPD | 1 (2.35) |
| Smoking | 10 (23.8) |
| Obesity | 3 (7.14) |
| Past abdominal surgery, n (%) | 10 (23.8) |
| Preop chemotherapy, n (%) | 13 (30.9) |
| Preop PTD, n (%) | 4 (9.4) |
| Preop ERCP, n (%) | 11 (26.2) |
| Preop surgical exploration, n (%) | 5 (11.9) |
| Preop albumin (mean ± SD) | 34.6 ± 4.94 |
| Preop albumin< 30, n (%) | 6 (14.28) |
| Preop bilirubin> 1, n (%) | 14 (33.3) |
BMI body mass index, HTN hypertension, DM diabetes mellitus, IHD ischemic heart disease, CHF congestive heart failure, CKD chronic kidney disease, HPL hyperlipidemia, BPH benign prostate hypertrophy, CVA cerebrovascular accident, COPD chronic obstructive pulmonary disease, PTD percutaneous transhepatic drainage, ERCP endoscopic retrograde cholangiopancreatography